RVMD Stock Analysis: Revolution Medicines | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 40.232m USD | 12M Return: 418.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 512M
Qual. Beats: -4
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Revolution Medicines (NASDAQ: RVMD) is a US-based, clinical-stage precision oncology company developing targeted therapies for cancers driven by RAS mutations. As a clinical-stage biotechnology, it has no approved products or commercial revenue from product sales, with its valuation tied to the progression of its R&D pipeline. The company was incorporated in 2014, completed its IPO in February 2020, and is headquartered in Redwood City, California.
The pipeline is built around two mechanisms: RAS(ON) inhibitors designed to bind active RAS protein variants, and RAS companion inhibitors that suppress cooperating pathways sustaining RAS-addicted tumors. Lead asset daraxonrasib (RMC-6236) is a pan-RAS(ON) inhibitor currently in a Phase 3 registrational trial in combination with zoldonrasib G12D (RMC-9805) in first-line pancreatic ductal adenocarcinoma (PDAC). Elironrasib G12C (RMC-6291) is in early clinical development for solid tumors. Earlier-stage candidates include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), each engineered against a specific RAS mutation.
- Daraxonrasib Phase 3 pancreatic cancer data readout approaches
- Cash burn accelerates ahead of multiple registrational trial milestones
- Competition intensifies from approved KRAS inhibitors Lumakras and Krazati
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.51 > 0.02 and ΔFCF/TA -25.66 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.47 > 3% & CFO -1.06b > Net Income -1.37b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (198.1m) vs 12m ago 5.29% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 11.06%; Δ -11.06% > 0%) |
| Interest Coverage Ratio: -36.65 > 6 (EBIT TTM -1.34b / Interest Expense TTM 36.5m) |
| A: 0.74 (Total Current Assets 1.97b - Total Current Liabilities 289.6m) / Total Assets 2.25b |
| B: -1.47 (Retained Earnings -3.32b / Total Assets 2.25b) |
| C: -0.58 (EBIT TTM -1.34b / Avg Total Assets 2.31b) |
| D: 1.99 (Book Value of Equity 1.50b / Total Liabilities 753.8m) |
| Altman-Z'' = -1.72 = D |
As of July 07, 2026, the stock is trading at USD 189.99 with a total of 2,267,385 shares traded. Over the past week, the price has changed by +4.34%, over one month by +27.95%, over three months by +99.23% and over the past year by +418.11%.
Current recommended Stop Loss: 181.60 (which is 4.4% or 1.2 ATR below the current price).
Revolution Medicines has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy RVMD.
- StrongBuy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 193 | 1.6% |
P/S = 9035.0954
P/B = 26.5541
Revenue TTM = 0.0 USD
EBIT TTM = -1.34b USD
EBITDA TTM = -1.32b USD
Long Term Debt = 420.7m USD (estimated: total debt 437.3m - short term 16.6m)
Short Term Debt = 16.6m USD (from shortTermDebt, last quarter)
Debt = 593.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 156.6m
Net Debt = -1.31b USD (calculated: Debt 593.9m - CCE 1.91b)
Enterprise Value = 38.9b USD (40.2b + Debt 593.9m - CCE 1.91b)
Interest Coverage Ratio = -36.65 (Ebit TTM -1.34b / Interest Expense TTM 36.5m)
EV/FCF = -33.57x (Enterprise Value 38.9b / FCF TTM -1.16b)
FCF Yield = -2.98% (FCF TTM -1.16b / Enterprise Value 38.9b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 16.6m) / Revenue TTM)
Tobins Q-Ratio = 17.27 (Enterprise Value 38.9b / Total Assets 2.25b)
Interest Expense / Debt = 6.14% (Interest Expense 36.5m / Debt 593.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -1.06b (EBIT -1.34b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.32 (Total Current Assets 1.97b / Total Current Liabilities 370.1m)
Debt / Equity = 0.40 (Debt 593.9m / totalStockholderEquity, last quarter 1.50b)
Debt / EBITDA = 1.00 (negative EBITDA) (Net Debt -1.31b / EBITDA -1.32b)
Debt / FCF = 1.13 (negative FCF - burning cash) (Net Debt -1.31b / FCF TTM -1.16b)
Total Stockholder Equity = 1.65b (last 4 quarters mean from totalStockholderEquity)
RoA = -59.39% (Net Income -1.37b / Total Assets 2.25b)
RoE = -83.22% (Net Income TTM -1.37b / Total Stockholder Equity 1.65b)
RoCE = -64.58% (EBIT -1.34b / Capital Employed (Equity 1.65b + L.T.Debt 420.7m))
RoIC = -53.29% (negative operating profit) (NOPAT -1.06b / Invested Capital 1.98b)
WACC = 10.72% (E(40.2b)/V(40.8b) * Re(10.81%) + D(593.9m)/V(40.8b) * Rd(6.14%) * (1-Tc(0.21)))
Discount Rate = 10.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 16.25%
[DCF] Fair Price = unknown (Cash Flow -1.16b)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -4
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.26 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-2.03 | Chg30d=-1.57% | Revisions=-72% | Analysts=18
EPS next Quarter (2026-09-30): EPS=-1.97 | Chg30d=-0.49% | Revisions=+6% | Analysts=18
EPS current Year (2026-12-31): EPS=-8.05 | Chg30d=-1.04% | Revisions=-67% | GrowthEPS=-35.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-5.81 | Chg30d=-2.69% | Revisions=-6% | GrowthEPS=+27.8% | GrowthRev=+687.3%
[Analyst] Revisions Ratio: -41% (up=18, down=45)